Bortezomib-Associated Demyelinating Neuropathy—Clinical and Pathologic Features
Authors:
- Kurenai TanjiKTKurenai Tanji
- Eduardo A. De SousaESEduardo A. De Sousa
- Louis H. WeimerLWLouis H. Weimer
- Thomas H. BrannaganTBThomas H. Brannagan
- 1 June 2015
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 16 (4) , 202-209
Abstract
Bortezomib is a proteasome inhibitor that is frequently used for multiple myeloma and lymphoma. A sensory predominant axonal neuropathy is associated with bortezomib treatment but a demyelinating neuropathy is also described primarily based on electrodiagnostic findings. We report a series of patients treated with bortezomib who developed peripheral neuropathy and were found to have demyelinating features on electrodiagnostic testing. Four patients who developed a bortezomib-induced peripheral neuropathy underwent electrophysiological testing, and 1 patient had a nerve biopsy. The four patients with bortezomib-induced peripheral neuropathy had demyelinating features on their electrophysiological testing. The nerve biopsy performed in 1 patient demonstrated a demyelinating component in a background of axonal degeneration. Although most toxic neuropathies are symmetrical axonal neuropathies, bortezomib is part of a small list of agents that may cause a demyelinating polyneuropathy and axonal degeneration. These findings have been confirmed by nerve biopsy.Keywords
This publication has 25 references indexed in Scilit:
- Bortezomib‐induced inflammatory neuropathyJournal of the Peripheral Nervous System, 2010
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continuesThe Lancet Oncology, 2010
- Neurological adverse effects caused by cytotoxic and targeted therapiesNature Reviews Clinical Oncology, 2009
- Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathyJournal of the Peripheral Nervous System, 2008
- Immune-mediated neuropathies in myeloma patients treated with bortezomibClinical Neurophysiology, 2008
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood, 2007
- Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literatureCancer, 2007
- Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the ratExperimental Neurology, 2007
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With BortezomibJournal of Clinical Oncology, 2006
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004